Individual lytic efficacy of recombinant tissue plasminogen activator in an in vitro human clot model: Rate of "nonresponse"

Academic Emergency Medicine

Volumn 20, Issue 5, 2013, Pages 449-455

  Meunier, Jason M ^a   Wenker, Evan ^a   Lindsell, Christopher J ^a   Shaw, George J ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b 705 Engineering Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

ADULT; ARTICLE; BLOOD CLOT; BLOOD CLOT RETRACTION; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; THERAPY EFFECT;

ADULT; BLOOD COAGULATION; CLOT RETRACTION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84877883561     PISSN: 10696563     EISSN: 15532712     Source Type: Journal    
DOI: 10.1111/acem.12133     Document Type: Article

References (46)

1. Grossbard EB,. Recombinant tissue plasminogen activator: a brief review. Pharm Res. 1987; 4: 375-8.
2. Tanswell P, Tebbe U, Neuhaus KL, Glasle-Schwarz L, Wojcik J, Seifried E,. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. J Am Coll Cardiol. 1992; 19: 1071-5.
3. Adams HP Jr, Brott TG, Furlan AJ, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Stroke. 1996; 27: 1711-8.
4. Bush RL, Lin PH, Lumsden AB,. Management of thrombosed dialysis access: thrombectomy versus thrombolysis. Semin Vasc Surg. 2004; 17: 32-9.
5. Madani H, Ransom PA,. Paradoxical embolus illustrating speed of action of recombinant tissue plasminogen activator in massive pulmonary embolism. Emerg Med J. 2007; 24: 441.
6. Khan IA, Gowda RM,. Clinical perspectives and therapeutics of thrombolysis. Int J Cardiol. 2003; 91: 115-27.
7. Stringer KA,. TIMI grade flow, mortality, and the GUSTO-III trial. Pharmacotherapy. 1998; 18: 699-705.
8. Ponec D, Irwin D, Haire WD, Hill PA, Li X, McCluskey ER,. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial-the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol. 2001; 12: 951-5.
9. Burgin WS, Malkoff M, Felberg RA, et al. Transcranial doppler ultrasound criteria for recanalization after thrombolysis for middle cerebral artery stroke. Stroke. 2000; 31: 1128-32.
10. Robbie LA, Booth NA, Croll AM, Bennett B,. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis. J Thromb Haemost. 1993; 70: 301-6.
11. Onundarson PT, Francis CW, Marder VJ,. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential. J Lab Clin Med. 1992; 120: 120-8.
12. Sabovic M, Lijnen HR, Keber D, Collen D,. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators. J Thromb Haemost. 1989; 62: 1083-7.
13. Clark JF, Huri DA, Carrozzella J, et al. Isoforms of apolipoprotein E can modulate tPA-induced clot lysis in vitro. Front Biosci. 2002; 7: a163-8.
14. van Diest R, Hamulyak K, Kop WJ, van Zandvoort C, Appels A,. Diurnal variations in coagulation and fibrinolysis in vital exhaustion. Psychosom Med. 2002; 64: 787-92.
15. Grimaudo V, Hauert J, Bachmann F, Kruithof EKO,. Diurnal-variation of the fibrinolytic system. J Thromb Haemost. 1988; 59: 495-9.
16. Shaw GJ, Sperling M, Meunier JM,. Long-term stability of recombinant tissue plasminogen activator at -80 C. BMC Res Notes. 2009; 2: 117.
17. Jaffe GJ, Green GD, Abrams GW,. Stability of recombinant tissue plasminogen activator. Am J Ophthalmol. 1989; 108: 90-1.
18. Francis CW, Onundarson PT, Carstensen EL, et al. Enhancement of fibrinolysis in vitro by ultrasound. J Clin Invest. 1992; 90: 2063-8.
19. Winter PM, Shukla HP, Caruthers SD, et al. Molecular imaging of human thrombus with computed tomography. Acad Radiol. 2005; 12 (Suppl 1): S9-13.
20. Yu X, Song SK, Chen J, et al. High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. Magn Reson Med. 2000; 44: 867-72.
21. Luo H, Steffen W, Cercek B, Arunasalam S, Maurer G, Siegel RJ,. Enhancement of thrombolysis by external ultrasound. Am Heart J. 1993; 125: 1564-9.
22. Francis C, Blinc A, Lee S, Cox C,. Ultrasound accelerates transport of recombinant tissue plasminogen activator into clots. Ultrasound Med Biol. 1995; 21: 419-24.
23. Loren M, Garcia Frade LJ, Torrado MC, Navarro JL,. Thrombus age and tissue plasminogen activator mediated thrombolysis in rats. Thromb Res. 1989; 56: 67-75.
24. Shaw GJ, Bavani N, Dhamija A, Lindsell CJ,. Effect of mild hypothermia on the thrombolytic efficacy of 120 kHz ultrasound enhanced thrombolysis in an in-vitro human clot model. Thromb Res. 2006; 117: 603-8.
25. Refaai MA, Van Cott EM, Lukoszyk M, Hughes J, Eby CS,. Loss of factor VIII and von Willebrand factor activities during cold storage of whole blood is reversed by rewarming. Lab Hematol. 2006; 12: 99-102.
26. Kaufman RM,. Uncommon cold: could 4 degrees C storage improve platelet function? Transfusion. 2005; 45: 1407-12.
27. Marinkovic SV, Miliasavljevic MM, Kovacevic MS, Stevia ZD,. Perforating branches of the middle cerebral artery: microanatomy and clinical significance of their intracerebral segments. Stroke. 1958; 15: 1022-9.
28. Tao X, Yu XJ, Bhattarai B, et al. Microsurgical anatomy of the anterior communicating artery complex in adult Chinese heads. Surg Neurol. 2006; 65: 151-61.
29. Cheng JY, Shaw GJ, Holland CK,. In vitro microscopic imaging of enhanced thrombolysis with 120-kHz ultrasound in a human clot model. Acoust Res Lett Online. 2005; 6: 25-9.
30. Shaw GJ, Meunier JM, Lindsell CJ, Pancioli AM, Holland CK,. Making the right choice: optimizing rt-PA and eptifibatide lysis, an in vitro study. Thromb Res. 2010; 126: e305-11.
31. Meunier JM, Holland CK, Lindsell CJ, Shaw GJ,. Duty cycle dependence of ultrasound enhanced thrombolysis in a human clot model. Ultrasound Med Biol. 2007; 33: 576-83.
32. Tanswell P, Seifried E, Su PC, Feuerer W, Rijken DC,. Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. Clin Pharmacol Ther. 1989; 46: 155-62.
33. Shaw GJ, Meunier JM, Lindsell CJ, Holland CK,. Tissue plasminogen activator concentration dependence of 120 kHz ultrasound-enhanced thrombolysis. Ultrasound Med Biol. 2008; 34: 1783-92.
34. Meunier JM, Smith DAB, Holland CK, Huang S, McPherson DD, Shaw GJ,. 120 kHz pulsed ultrasound enhanced thrombolysis with tissue plasminogen activator-loaded echogenic liposomes [abstract]. J Acoust Soc Am. 2007; 122 (5 Pt 2): 3052.
35. Colucci M, Scopece S, Gelato AV, Dimonte D, Semeraro N,. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis-study in healthy subjects and correlation with blood fibrinolytic parameters. Thromb Haemost. 1997; 77: 725-9.
36. Trusen B, Ries M, Zenker M, et al. Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA). Semin Thromb Hemost. 1998; 24: 599-604.
37. Niessen F, Hilger T, Hoehn M, Hossmann KA,. Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental thromboembolic stroke. Stroke. 2003; 34: 2019-24.
38. Silvain J, Collet JP, Nagaswami C, et al. Composition of coronary thrombus in acute myocardial infarction. J Am Coll Cardiol. 2011; 57: 1359-67.
39. Liebeskind DS, Sanossian N, Yong WH, et al. CT and MRI early vessel signs reflect clot composition in acute stroke. Stroke. 2011; 42: 1237-43.
40. Robbie LA, Bennett B, Croll AM, Brown PA, Booth NA,. Proteins of the fibrinolytic system in human thrombi. Thromb Haemost. 1996; 75: 127-33.
41. Ribo M, Montaner J, Molina CA, Arenillas JF, Santamarina E, Alvarez-Sabin J,. Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thromb Haemost. 2004; 91: 1146-51.
42. Potter van Loon BJ, Rijken DC, Brommer EJ, van der Maas AP,. The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemost. 1992; 67: 101-5.
43. Pancioli AM, Broderick J, Brott T, et al. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke. 2008; 39: 3268-76.
44. Marder VJ, Jahan R, Gruber T, Goyal A, Arora V,. Thrombolysis with plasmin: implications for stroke treatment. Stroke. 2010; 41 (10 Suppl): S45-9.
45. Shaw GJ, Meunier JM, Huang SL, Lindsell CJ, McPherson DD, Holland CK,. Ultrasound-enhanced thrombolysis with tPA-loaded echogenic liposomes. Thromb Res. 2009; 124: 306-10.
46. Diamond SL, Anand S,. Inner clot diffusion and permeating during fibrinolysis. Biophys J. 1993; 65: 2622-43.